Biologics
Antibody-based therapeutics
Integrating our multi-faceted experiences in protein engineering technologies and deep CMC expertise to
create the next generation of novel and valuable biologics
- Antibody-based therapeutics
- Bispecific antibodies
- Fusion proteins
- Immunocytokines
- Immune cell engagers
- Antibody Drug Conjugates (ADC)
Biosimilar
- Enabling technology for manufacturing process of recombinant biologics
- Expertise and scientific know-hows to ensure biosimilarity
- Scientific capabilities for all developmental phases from cell line development to commercial manufacturing process
| Code | Therapeutic Area | Status |
|---|---|---|
| DA-3880 (Darbepoetin) |
Hematology | Launched (Japan) |
| DMB-3115 (Ustekinumab) |
Immunology | Phase 3 completion |
| DMB-3116 (Pembrolizumab) |
Oncology | Preclincal |
| DA-3007 (Iong acting hGH) |
Endocrinology | Preclincal |